Lasmiditan Passes Phase II Study
Another entry in the race to develop a new generation of migraine treatments is showing promise. Lasmiditan (also known as COL-144) was found to be effective for acute migraine attacks in a Phase IIb study. CoLucid Pharmaceuticals, Inc. describes the…
Read More